Back to search

National and Kapodistrian University of Athens

Λειτουργική αξιολόγηση γνωστών παραλλαγών αγνώστου κλινικής σημασίας κια χαρακτηρισμός νέων μεταλλάξεων σε γονίδια που εμπλέκονται στον κληρονομικό καρκίνο μαστού - ωοθηκών

Abstract

dc:description

In the human body, cells respond to DNA damage by inducing cell-cycle arrest at its checkpoints, as well as by activating DNA repair mechanisms. Failure of these processes may lead to apoptosis or carcinogenesis.Cellular response is regulated by a network of signaling pathways with the participation of multiple molecules, among which CHK2, NEK1, BRCA1 and BRCA2, that were studied in the present thesis, play a crucial role.CHK2 protein is a phylogenetically conserved serine-threonine kinase, which participates in cell-cycle arrest, activation of DNA repair mechanisms and apoptosis, through phosphorylation of several substrates. NEK1 protein, which exhibits dual kinase activity, namely serine-threonine and tyrosine, plays an important role in cellular response, as it contributes to CHK1 and CHK2 activation, proper function of ATR pathway, as well as maintenance of chromosomal stability. On the other hand, BRCA1 and BRCA2 molecules participate in homologous recombination repair, which is the most important and error-free mechanism for repairing double-strand DNA breaks, after the S-phase. BRCA1 plays a key role in this mechanism, as it participates in the creation of at least four functionally-distinct complexes. In parallel, it participates in cell-cycle arrest, through the ATR-CHK1 pathway and by interacting with the p53 transcription factor. Finally, involvement of BRCA1 in other DNA repair mechanisms has also been suggested.The significance of the above molecules in cellular processes is proven by the impact of relative genetic variants on the carriers’ phenotypes.CHEK2 gene mutations have been associated with cancer predisposition, mainly of the breast, colon, prostate, gastric and thyroid. The use of new molecular methods of massive parallel sequencing in cancer patient genetic testing has revealed a plethora of findings in this gene, the majority of which are variants of unknown clinical significance. The need for clinical management of these patients and the rarity of CHEK2 variants in epidemiological studies, prompted us in developing a functional assay for variant evaluation in the context of this study, using Saccharomyces cerevisiae as a model system.With the use of this functional assay, 122 CHEK2 variants were analyzed, namely 120 missense variants and 2 large in-frame deletions. Comparison of the growth rate of these strains with both positive and negative controls, showed that 32 missense variants and the 2 in-frame deletions behaved as non-functional (pathogenic), 73 as functional (benign) and 15 as semi-functional (intermediate). The majority of pathogenic variants was located in the CHK2 kinase and FHA domains. Simultaneously, comparison of computational analysis results with those from the functional assay revealed agreement for the majority of variants that were characterized as pathogenic. In addition, the assay-obtained characterization was consistent with strong breast cancer family history, where data were available. Comparison of our present study results with data from other functional assays revealed agreement for 9 out of 18 variants that were alanyzed, whereas a structural model was used for some variants, in order to predict the relative effect on the structure and function of the produced protein. This study, which is the largest to-date analysis of CHEK2 variants globally, may contribute to the final classification of rare CHEK2 variants of uncertain clinical significance.On the other hand, NEK1 mutations have been previously associated with amyotrophic lateral sclerosis and short-rib polydactyly syndrome-type II. Identification of two NEK1 variants, in exons 20 and 26, in pancreatic cancer patients during genetic testing, in a recently published study, prompted us to analyze 181 DNA samples from peripheral blood of pancreatic adenocarcinoma patients for genetic mutations in exons 20, 21, 22, 25 and 26 of NEK1 gene.Analysis revealed three missense variants, namely p.ΑΙa626Thr, p.Αsn745Lys and p.Glu752Gly, in 11.6%, 0.01% and 19.9% of the samples, respectively. Although the majority of in silico tools used for analysis indicated pathogenicity of these variants, data collected from international databases were in disagreement with this characterization. Therefore, no correlation of NEK1 variants with pancreatic cancer occurrence was proven in the present study.Regarding BRCA1 and BRCA2, pathogenic genetic variants in these genes have been associated with breast and ovarian cancer, as well as with pancreatic, prostate, gastric and colon cancer. The involvement of these molecules in DNA repair mechanism through homologous recombination was the basis for the development of a targeted therapy using PARP inhibitors, which combines the simultaneous deficiency of single- and double-stand break repair mechanisms, resulting in “synthetic lethality” of cancer cells.Due to the high frequency of BRCA1/2 mutations in epithelial ovarian carcinoma tissue samples, mainly in high-grade serous carcinomas, as described in recently published studies, 133 formalin-fixed paraffin-embedded tissue samples from epithelial ovarian cancer patients, were analyzed for somatic mutations in BRCA1 and BRCA2 genes. Pathogenic variants in BRCA1 and BRCA2 genes were identified in 15 and 2 samples (in total 12.8%), respectively, most common of which was the p.Val1833Met variant identified in 5 samples. As a result of the analysis, patients carrying these somatic mutations have already been included in therapeutic protocols with PARP inhibitors.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Delimitsou, Angeliki
  • Δελημήτσου, Αγγελική

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/45868

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Delimitsou, Angeliki; Δελημήτσου, Αγγελική. Λειτουργική αξιολόγηση γνωστών παραλλαγών αγνώστου κλινικής σημασίας κια χαρακτηρισμός νέων μεταλλάξεων σε γονίδια που εμπλέκονται στον κληρονομικό καρκίνο μαστού - ωοθηκών. National and Kapodistrian University of Athens, 2019. http://hdl.handle.net/10442/hedi/45868